| |
Infusion 1
|
Infusion 2
|
Infusion 3
|
Infusion 4
|
|---|
|
Received infusion
|
351a
|
341a
|
290b
|
278
|
|
Infusion at the faster rate
|
NA
|
337
|
289
|
278
|
|
Completed 1000 mgc
|
338
|
333
|
288
|
277
|
|
Total infusion hours
|
|
n
|
338
|
333
|
288
|
277
|
|
Mean (SD)
|
4.4 (0.3)
|
2.0 (0.1)
|
2.1 (0.3)
|
2.0 (0.1)
|
|
Range
|
4.1-6.4
|
1.8-3.2
|
1.9-4.3
|
1.9-2.4
|
|
> 2.5 h
|
338 (100%)
|
5 (1.5%)
|
12 (4.2%)
|
0
|
|
> 4.5 h
|
41 (12.1%)
|
0
|
0
|
0
|
- NA, not applicable; SD, standard deviation. aInfusion rate and dose could not be determined for 4 patients because the site failed to record the infusion volume. Of these 4 patients, 3 at Day 168 and 2 at Day 182 received rituximab at the faster rate. bRituximab was administered at the standard infusion rate in 1 patient. cRituximab dose was derived from the sum of the volume received at each segment. To account for truncation errors, the derived dose of 970 mg or larger was considered as completed 1000 mg.
